Thonzylamine Hydrochloride/Tritoqualine

Total Page:16

File Type:pdf, Size:1020Kb

Load more

Thonzylamine Hydrochloride/Tritoqualine 593 Adverse Effects and Precautions and rhinitis (p.565), and in pruritic skin disorders Med-Actigen†; Medofed; Milafed; Nanafed†; Nasolin†; Nostrilet; Policol; Policold; Polyfed; Pondactil; Profed; Prophedin; Sinusaid; Sufed; Trifed; Tri- As for the sedating antihistamines in general, p.561. (p.565). It is often used in combination with pseu- ofed; Tripo; Triprodrine; Vefed†; Vesprolid-HCL; Turk.: A-ferin; Actidem; UK product information for acrivastine has warned doephedrine hydrochloride for rhinitis and in other Actifed; UAE: Sedofan; Sedofan DM; UK: Benylin Childrens Coughs & Colds; Multi-Action Actifed; Multi-Action Actifed Chesty Coughs Expecto- that acrivastine should not be used in patients hyper- compound preparations for the symptomatic treatment rant; Multi-Action Actifed Dry Coughs; Sudafed Plus; USA: Actagen; Acta- sensitive to triprolidine. of coughs and the common cold (p.564). gen-C Cough; Actifed; Actifed Cold & Allergy; Actifed Cold & Sinus; Actifed Plus; Allercon; Allerfrim; Allerfrim with Codeine; Allerphed; Aprodine; Breast feeding. No adverse effects have been seen in breast- It is given orally, the usual dose for adults being 2.5 mg Aprodine with Codeine; Bayer Select Night Time Cold; Cenafed Plus; fed infants whose mothers were receiving triprolidine, and the up to four times daily. Genac; Silafed; Trifed-C Cough; Triofed; Tripohist D; Triposed; Zymine HC; 1 Zymine-D; Venez.: Actifed†. American Academy of Pediatrics considers that it is therefore Triprolidine tannate has been used similarly. usually compatible with breast feeding. In a study2 in 3 women of the excretion of triprolidine and pseu- Triprolidine hydrochloride has also been applied topi- doephedrine, taken orally in a combined preparation, triprolidine cally to the skin although, as with other antihistamines, Tritoqualine (rINN) was found to reach concentrations in breast milk similar to those there is a risk of sensitisation. L-554; Tritocualina; Tritoqualinum. 7-Amino-4,5,6-triethoxy-3- found in plasma in one subject, and slightly lower than in plasma (5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo[4,5-g]iso- in the others. It was calculated that 0.06 to 0.2% of the ingested Preparations quinolin-5-yl)phthalide. dose was distributed into breast milk over 24 hours. Concentra- BP 2008: Triprolidine Tablets; tions of pseudoephedrine in breast milk exceeded those in plas- USP 31: Triprolidine and Pseudoephedrine Hydrochlorides Syrup; Tripro- Тритоквалин ma in all 3 women. lidine and Pseudoephedrine Hydrochlorides Tablets; Triprolidine Hydro- chloride Syrup; Triprolidine Hydrochloride Tablets. C26H32N2O8 = 500.5. 1. American Academy of Pediatrics. The transfer of drugs and oth- CAS — 14504-73-5. Proprietary Preparations (details are given in Part 3) er chemicals into human milk. Pediatrics 2001; 108: 776–89. ATC — R06AX21. Correction. ibid.; 1029. Also available at: Israel: Pro-Actidil†; Ital.: Actidil†; Spain: Pro-Actidil†; UAE: Sedofan T; http://aappolicy.aappublications.org/cgi/content/full/ USA: Zymine. ATC Vet — QR06AX21. pediatrics%3b108/3/776 (accessed 30/01/04) Multi-ingredient: Arg.: Actifedrin; Austral.: Actifed; Actifed CC Junior; 2. Findlay JWA, et al. Pseudoephedrine and triprolidine in plasma Codral Original Day & Night Cold & Flu; Sudafed Sinus Day & Night Relief; and breast milk of nursing mothers. Br J Clin Pharmacol 1984; Sudafed Sinus Pain & Allergy Relief; Belg.: Actifed; Braz.: Actifedrin; Trife- 18: 901–6. drin; Canad.: Actifed; Actifed Plus; CoActifed; Covan†; ratio-Cotridin; ra- H3C tio-Cotridin Expectorant; Chile: Actifedrin; Actifedrin Antitusivo; Cz.: CH3 Trifed Expectorant†; Trifed†; Fr.: Actifed; Actifed Toux Seche†; Ger.: Rhi- N Interactions nopront Kombi; Hong Kong: Actifed; Actifed Compound; Actifed DM†; O As for the sedating antihistamines in general, p.563. Actihist-Co†; Antifort; Cough-EN†; Fedac; Fedac Compound; Prolifed; Set- CH3 prodine†; Syncofit; Uni-Fedra Compound; Vidalidine; India: Actifed DM†; O O Actifed Plus†; Actifed†; Actiflu; Actiflu Plus; Ascoril-D+; Deletus; Deletus D; Pharmacokinetics Nocold Plus; Indon.: Actifed; Actifed DM; Actifed Expectorant; Actigesic; Alerfed; Crofed; Eflin; Flutrop; Lapifed; Lapifed DM; Lapifed Expectorant; O O After absorption from the gastrointestinal tract, tripro- O O Nasafed; Nasafed Plus; Nichofed; Nostel; Protifed; Stop Cold; Tremenza; H C lidine is metabolised; a carboxylated derivative ac- Trifed; Trifedrin; Valved; Valved DM; Irl.: Actifed; Actifed Chesty†; Actifed 3 Compound†; Benylin Childrens Cough and Cold; Benylin Dual Action Dry; NH CH counts for about half the dose excreted in the urine. Re- Israel: Actifed Compound†; Actifed DM†; Actifed Expectorant†; Actifed†; O 2 3 ported half-lives vary from 3 to 5 hours or more. Histafed; Histafed Comp; Histafed Expectorant; Sinufed Kid Night†; Ital.: Actifed; Actifed Composto; Actigrip; Malaysia: Actifed; Actifed DM; Ac- Triprolidine is distributed into breast milk. tifed Expectorant; Actihist; Actihist Expectorant; Actihist-Co; Axcel Tridine; Profile Beatafed; Beatafed Compound†; Cough-EN; Decol; Fedac; Pabron Cold & Tritoqualine is stated to inhibit histidine decarboxylase which ca- ◊ General references. Flu; Pabron Cough & Sinus; Pabron Cough-D; Peace; Pseudoephedrine T; talyses the conversion of histidine to histamine. It has no action 1. Paton DM, Webster DR. Clinical pharmacokinetics of H -recep- Rhynacol; Mex.: Actifed; Actifed DM; Giparlix; NZ: Actifed; Codral Day- on histamine H -receptors and at therapeutic doses has no seda- tor antagonists (the antihistamines). Clin Pharmacokinet 1985; time/Nightime; Sudafed Day/Nightime Relief; Sudafed Sinus Pain & Allergy 1 10: 477–97. Relief; Pol.: Actifed; Actitrin; Port.: Actifed; Dinaxil; S.Afr.: Actifed; Actifed tive or antimuscarinic effects. It has the uses of antihistamines 2. Miles MV, et al. Pharmacokinetics of oral and transdermal Cold & Fever; Actifed Dry Cough Regular; Actifed Dry Cough Sugar Free; (p.563) and has been given orally in usual doses of 200 to triprolidine. J Clin Pharmacol 1990; 30: 572–5. Acuflu P; Acugest; Acugest Co; Acugest DM; Acugest Expect; Acutussive; 600 mg daily in 2 or 3 divided doses for the symptomatic relief Adco-Flupain; Adco-Tussend; Betafed; Coff-Rest†; Coryx; Endcol Cough of hypersensitivity reactions including allergic rhinitis and urti- Linctus†; Endcol DM†; Endcol Expectorant†; Fludactil Co; Fludactil Expec- Uses and Administration torant†; Fludactil†; Linctifed; Medifed; Merck-Cough Linctus; Merck-Expec- caria. Triprolidine hydrochloride, an alkylamine derivative, torant; Merck-Fed; Neofed†; Sinuclear; Tixylix Flu; Trifen; Singapore: 3P†; Preparations Actifed; Actifed Compound; Actifed DM; Actifed Expectorant; Beactafed; is a sedating antihistamine with antimuscarinic and Beactafed Co; Cough-EN; Fedac; Fedac Compound; Peacef; Trodrine†; Proprietary Preparations (details are given in Part 3) mild sedative effects. It is used for the symptomatic re- Unitifed†; Spain: Iniston Antitusivo y Descongestivo; Iniston Desconges- Austria: Hypostamin; Fr.: Hypostamine; Ger.: Inhibostamin†. tivo; Iniston Expectorante y Descongestivo; Thai.: Actifed; Actifed Com- lief of allergic conditions including urticaria (p.565) pound†; Actifed DM; Actil; Actiplex; Clinikold; Cofed; Consudine; Hiscifed; The symbol † denotes a preparation no longer actively marketed The symbol ⊗ denotes a substance whose use may be restricted in certain sports (see p.vii) Antimalarials/Amodiaquine 597 en at intervals at least one month apart. For maximum ben- 14. Lengeler C. Insecticide-treated bed nets and curtains for pre- soning. However, large doses of amodiaquine have been report- efit 2 to 3 doses of IPT should be given. For further venting malaria. Available in The Cochrane Database of Sys- ed to produce syncope, spasticity, convulsions, and involuntary tematic Reviews; Issue 2. Chichester: John Wiley; 2004 (ac- 9 information on the use of pyrimethamine in pregnancy, see cessed 18/08/05). movements. under Precautions for Pyrimethamine, p.611. In areas of 15. CDC. Malaria. In: The Yellow Book: CDC Health Information 1. Anonymous. Amodiaquine and agranulocytosis. WHO Drug Inf for International Travel; 2008. Available at: 1987; 1: 5–6. low or unstable malaria transmission, where pregnant http://wwwn.cdc.gov/travel/yellowBookCh4-Malaria.aspx (ac- 2. Larrey D, et al. Amodiaquine-induced hepatitis. Ann Intern Med women have low immunity to malaria, use of insecticide- cessed 28/09/07) 1986; 104: 801–3. treated nets and prompt case management of pregnant 16. Chiodini P, et al. HPA Advisory Committee on Malaria Preven- 3. Phillips-Howard PA, West LJ. Serious adverse drug reactions to tion in UK Travellers. Guidelines for malaria prevention in trav- pyrimethamine–sulphadoxine, pyrimethamine–dapsone and to women with fever and malarial illness is recommended. In ellers from the United Kingdom (issued 01/07). Available at: amodiaquine in Britain. J R Soc Med 1990; 83: 82–5. addition, all pregnant women should take iron and folate http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/ 4. Anonymous. Development of recommendations for the protec- supplements. 1203496943523 (accessed 17/06/08) tion of short-stay travellers to malaria endemic areas: memoran- dum from two WHO meetings. Bull WHO 1988; 66: 177–96. Prophylaxis during breast feeding. It is generally ac- 5. Olliaro P, et al. Systematic review of amodiaquine treatment in cepted for most antimalarials that the amounts distributed uncomplicated malaria. Lancet 1996;
Recommended publications
  • A Simple Question... Histamine

    A Simple Question... Histamine

    A simple question... How was histamine discovered ? • by chemical synthesis … • from the analysis of plant extracts (ergot fungus Claviceps purpurea) • from the analysis of animal tissues extracts • through none of these approaches Antihistamines 21/03/2010 1 Histamine ... obtained by synthetic chemist in 1907 …as a chemical curiosity … detection of an identical compound in an extract from ergot fungus … and shown to cause a marked vasodilatation a similar effect is seen with tissues extracts produces a similar picture as a very severe allergic reaction recognized as a "biological" molecule (and not a product from putrefaction in 1927 ... Antihistamines 21/03/2010 2 1 From histidine to histamine ... HN HN CH CH NH 2 2 CH2 CH2 NH2 N COOH N L-histidine decarboxylase First inhibitor tritoqualine of histmine action … commercialized in France (HYPOSTAMINE ) Antihistamines 21/03/2010 3 Localization of histamine total blood leucocytes mastocytes 1. blood plasma other leucocytes 2. tissues ... the word comes from ("histos" = tissue !!) • skin • lung • gastrointestinal tract • central nervous system Antihistamines 21/03/2010 4 2 Actions of histamine • of capillary permability and vasodilatation cutaneous rednesses signs inflammation • bronchoconstriction important with the guinea-pig but under H2 retrocontol in man • of HCl secretion (pariteal cells of the stomach) • neurotransmission awakening reactions, tachycardia, hypertension nauseas, vomitting migraines neurological and comportmental signs Antihistamines 21/03/2010 5 Rappel:
  • (CD-P-PH/PHO) Report Classification/Justifica

    (CD-P-PH/PHO) Report Classification/Justifica

    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group R01 (Nasal preparations) Table of Contents Page INTRODUCTION 5 DISCLAIMER 7 GLOSSARY OF TERMS USED IN THIS DOCUMENT 8 ACTIVE SUBSTANCES Cyclopentamine (ATC: R01AA02) 10 Ephedrine (ATC: R01AA03) 11 Phenylephrine (ATC: R01AA04) 14 Oxymetazoline (ATC: R01AA05) 16 Tetryzoline (ATC: R01AA06) 19 Xylometazoline (ATC: R01AA07) 20 Naphazoline (ATC: R01AA08) 23 Tramazoline (ATC: R01AA09) 26 Metizoline (ATC: R01AA10) 29 Tuaminoheptane (ATC: R01AA11) 30 Fenoxazoline (ATC: R01AA12) 31 Tymazoline (ATC: R01AA13) 32 Epinephrine (ATC: R01AA14) 33 Indanazoline (ATC: R01AA15) 34 Phenylephrine (ATC: R01AB01) 35 Naphazoline (ATC: R01AB02) 37 Tetryzoline (ATC: R01AB03) 39 Ephedrine (ATC: R01AB05) 40 Xylometazoline (ATC: R01AB06) 41 Oxymetazoline (ATC: R01AB07) 45 Tuaminoheptane (ATC: R01AB08) 46 Cromoglicic Acid (ATC: R01AC01) 49 2 Levocabastine (ATC: R01AC02) 51 Azelastine (ATC: R01AC03) 53 Antazoline (ATC: R01AC04) 56 Spaglumic Acid (ATC: R01AC05) 57 Thonzylamine (ATC: R01AC06) 58 Nedocromil (ATC: R01AC07) 59 Olopatadine (ATC: R01AC08) 60 Cromoglicic Acid, Combinations (ATC: R01AC51) 61 Beclometasone (ATC: R01AD01) 62 Prednisolone (ATC: R01AD02) 66 Dexamethasone (ATC: R01AD03) 67 Flunisolide (ATC: R01AD04) 68 Budesonide (ATC: R01AD05) 69 Betamethasone (ATC: R01AD06) 72 Tixocortol (ATC: R01AD07) 73 Fluticasone (ATC: R01AD08) 74 Mometasone (ATC: R01AD09) 78 Triamcinolone (ATC: R01AD11) 82
  • United States Patent [191 [11] Patent Number: 5,696,273 Andre Et A]

    United States Patent [191 [11] Patent Number: 5,696,273 Andre Et A]

    USOO5696273A United States Patent [191 [11] Patent Number: 5,696,273 Andre et a]. [45] Date of Patent: Dec. 9, 1997 [54] METHOD FOR SYNTHESIZING OTHER PUBLICATIONS CUCURBITINE Pn'ce. Pathophysiology. Clinical Concepts of Disease Pro [75] Inventors: Patrice Andre. Neuvilles aux Bois; cess~ 19,36~ PP- 36-37- ‘ _ valérie Thiery_ Clery St Andre; Gémld Webster s New World Dictionary. 1988. p. 36. Guillaumet‘ 01-16mm an of France World Patents Index Latest. AN 87-32998? [47]. Derwent Publications Ltd.. London. GB. & JP. S. 62234013 (Osaka [73] Assignee: Parfums Christian Dior. Paris. France Yak'lhin Kmky) 14 Oct- 1937 Chemical Abstract. vol. 82. No. 23. 1975. p. 40. abstract _ 149446a. Pharmacological (anthelminthic) study of Cucur [21] APPL N°" 476’646 bita. ,A.E. Gonzalez a a1. [22] Filed; Jm 7, 1995 Scienta Sinica. vol. X. No. 7. 1961.T.-T. Sun et a1. “Chemi cal studies on cucurbita moschata duch". pp. 852-859. Related US. Application Data Journal of the Chemical Society. Chemical Communica tions. 1973. H]. Monteiro, “New synthesis of the ami [62] Division of Ser. No. 108,601 , ?led as PCT/FR92/00164 Feb. no-acid (+)-Cucurbitine”. p. 2. 24’ 1992, abandmed- Chemical and Pharmaceutical Bulletin. vol. 35. No. 9. Sep. [30] Foreign. Application. Pl'lol'lty. Data ..'. 5183;135:2149?' t.‘ nzym esandcatalsts.H.Pi y g Feb. 28, 1991 [FR] France ................................. .. 9102420 J. Fable. “Methoden der Organischen Chemie". vol. E5. Georg Thieme Verlag pp. 534-543. (1973). [5 .................... .. C071) 207/36 Derwent Publications Ltd. 52051033AN (Ogawa) 23 Apr.& 1977. [52] US. Cl. 548/531; 548/542; 548/550 world Patents Indcx Latest, 1937‘ AN 37473336 [39]_ [58] Field of Search 5481531.
  • Prohibited Substances List

    Prohibited Substances List

    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
  • (19) United States (12) Patent Application Publication (10) Pub

    (19) United States (12) Patent Application Publication (10) Pub

    US 20130210835A1 (19) United States (12) Patent Application Publication (10) Pub. N0.2 US 2013/0210835 A1 Mitchell (43) Pub. Date: Aug. 15, 2013 (54) PHARMACEUTICAL COMPOSITIONS Publication Classi?cation (75) Inventor: Odes W. Mitchell; Arlington, TX (U S) (51) Int. Cl. A61K31/137 (2006.01) _ A611; 31/4402 (2006.01) (73) Ass1gnee: GM PHARMACEUTICAL, INC, A61K 31/485 (200601) Arhngton, TX (Us) A611; 31/09 (2006.01) _ A611; 31/495 (2006.01) (21) App1.No.. 13/703,584 A61K31/505 (200601) 22 PCT P1 d: J .13 2011 (52) us Cl ( ) 1e “n ’ CPC ........... .. A611; 31/137 (2013.01); A611;31/495 (86) PCT NO. PCT/“11,4031 (2013.01); A611;31/505 (2013.01); A611; 31/485 (2013.01); A611; 31/09 (2013.01); § 371 (0)0). A611;31/4402 (2013.01) (2), (4) Date: Feb- 2, 2013 USPC .... .. 514/255.04; 564/355; 514/653; 544/396; 544/332; 514/275; 546/74; 514/289; 514/282; Related US. Application Data 514657; 514652 (60) Provisional application No. 61/354,061; ?led on Jun. (57) ABSTRACT 11; 2010; provisional application No. 61/354,057; A composition of an antitussive; a decongestant; or an anti ?led on Jun. 11; 2010; provisional application No. histamine to treat respiratory and oral pharyngeal congestion 61/354,053; ?led on Jun. 11,2010. and related symptoms in a patient. US 2013/0210835 A1 Aug. 15,2013 PHARMACEUTICAL COMPOSITIONS mucus build-up to clear congestion in the air passages. Symp toms due to allergies or allergens are often treated With an CROSS-REFERENCES TO RELATED antihistamine.
  • Selective Reaction Monitoring (SRM) Daten Von Mehr Als 900 Xenobiotika Für Aufbau Und Validierung Von LC-MS/MS Analysen

    Selective Reaction Monitoring (SRM) Daten Von Mehr Als 900 Xenobiotika Für Aufbau Und Validierung Von LC-MS/MS Analysen

    T + K (2008) 75 (3): 149 Selective Reaction Monitoring (SRM) Daten von mehr als 900 Xenobiotika für Aufbau und Validierung von LC-MS/MS Analysen Brunhilde Güssregen, Stefanie Schröfel, Markus Nauck, Torsten Arndt Bioscientia Institut für Medizinische Diagnostik GmbH, Konrad-Adenauer-Str. 17, 55218 Ingelheim; e-mail: [email protected] Die Flüssigkeitschromatographie-Tandem-Massenspektrometrie (LC-MS/MS) hat in den letz- ten Jahren eine zunehmende Bedeutung nicht nur in der klinisch-chemischen sondern auch in der toxikologischen Analytik gewonnen. Sie kann heute neben den klassischen Verfahren wie UV/VIS-Spektrometrie, Hochleistungs-Flüssigkeitschromatographie (HPLC) und Gaschro- matographie-Massenspektrometrie (GC-MS) als integraler Bestandteil der qualitativen und quantitativen Analytik gewertet werden. Dies drückt sich nicht zuletzt in der steigenden Zahl der Meldungen von mit LC-MS/MS erhobenen GTFCh- Ringversuchsergebnissen aus. Die Ursachen für diese Popularität sind vielfältig. Es sind u. a. einige analytische Vorteile im Vergleich zu den o. g. Analysentechniken: Vereinfachte Probenvorbereitung (z. B. ohne Derivatisierungsreaktionen), Einsatz geringerer Probenmengen, Kürzere Chromatographie- und dadurch Analysezeiten, Spezifitätssteigerung durch die Kombination von minimal 4 Identifizierungskriterien (Retentionszeit, Massenübergänge 1 und 2 [SRM 1 und SRM 2], Intensitätsverhältnis von SRM1 und SRM2), deren Anzahl bei Verwendung von mehr als 2 SRM erhöht werden kann, Eignung für alle löslichen Substanzen unabhängig von ihrer Fähigkeit, zerstörungs- frei in die Gasphase überführt werden zu können. Derzeitige Nachteile der LC-MS/MS im Methodenvergleich sind: Fehlende Standardisierung sowohl der Chromatographie- als auch der Tandem-Mas- senspektrometrie-Analysenteilschritte, Variabilität der Massenspektren infolge der vglw. milden Fragmentierungsbedingun- gen, Fehlen von allgemein verfügbaren LC-MS/MS-Spektren- und/oder Massenübergangs (SRM)-Bibliotheken mit einer der Pfleger-Maurer-Weber Bibliothek [1] oder der Pragst et al.
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances

    The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances

    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
  • 236 Subpart A—General Provisions Subpart B—Active Ingredients

    236 Subpart A—General Provisions Subpart B—Active Ingredients

    § 341.1 21 CFR Ch. I (4–1–01 Edition) 341.78 Labeling of expectorant drug prod- (g) Topical nasal decongestant drug. A ucts. drug that when applied topically inside 341.80 Labeling of nasal decongestant drug the nose, in the form of drops, jellies, products. or sprays, or when inhaled intranasally 341.90 Professional labeling. reduces nasal congestion caused by AUTHORITY: 21 U.S.C. 321, 351, 352, 353, 355, acute or chronic rhinitis. 360, 371. (h) Calibrated dropper. A dropper cali- brated such that the volume error in- Subpart A—General Provisions curred in measuring any liquid does not exceed 15 percent under normal use § 341.1 Scope. conditions. (a) An over-the-counter cold, cough, [51 FR 35339, Oct. 2, 1986, as amended at 54 FR allergy, bronchodilator, or anti- 8509, Feb. 28, 1989; 55 FR 40382, Oct. 3, 1990; 57 asthmatic drug product in a form suit- FR 58374, Dec. 9, 1992; 59 FR 43409, Aug. 23, able for oral, inhalant, or topical ad- 1994] ministration is generally recognized as safe and effective and is not mis- Subpart B—Active Ingredients branded if it meets each of the condi- tions in this part and each of the gen- § 341.12 Antihistamine active ingredi- eral conditions established in § 330.1. ents. (b) References in this part to regu- The active ingredient of the product latory sections of the Code of Federal consists of any of the following when Regulations are to chapter I of title 21 used within the dosage limits estab- unless otherwise noted. lished for each ingredient: [51 FR 35339, Oct.
  • Pharmaceutical Appendix to the Tariff Schedule 2

    Pharmaceutical Appendix to the Tariff Schedule 2

    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
  • Proposed Changes to the 2021 FEI Equine Prohibited Substances List (EPSL) (Effective from 01.01.2022)

    Proposed Changes to the 2021 FEI Equine Prohibited Substances List (EPSL) (Effective from 01.01.2022)

    Proposed changes to the 2021 FEI Equine Prohibited Substances List (EPSL) (effective from 01.01.2022) SUBSTANCE NAME CURRENT PROPOSED COMMENT STATUS EPSL CATEGORY ACETYLCHOLINESTERASE INHIBITOR Used in the treatment of Edrophonium Controlled Banned myasthenia gravis and Medication Substance has no legitimate use in the treatment of sports horses Used to increase Huperzine A Unlisted Banned alertness and treat Substance myasthenia gravis. The substance has no legitimate use in the treatment of sports horses. AMIDES Palmitoylethanolamid Banned Controlled Used in the treatment of Substance Medication joint pain ANGIOTENSIN CONVERTING ENZYME INHIBITORS Enalapril Controlled Banned The substance carries a Medication Substance high risk of abuse and has no legitimate use in the sports horse Enalaprilat Controlled Banned The substance carries a Medication Substance high risk of abuse and has no legitimate use in the sports horse Lisinopril Controlled Banned The substance carries a Medication Substance high risk of abuse and has no legitimate use in the sports horse Moexipril Controlled Banned The substance carries a Medication Substance high risk of abuse and has no legitimate use in the sports horse 1 Perindoprilat Controlled Banned The substance carries a Medication Substance high risk of abuse and has no legitimate use in the sports horse ANTIHISTAMINES Antazoline Controlled Banned The substance has no Medication Substance legitimate use in the sports horse Azatadine Controlled Banned The substance has Medication Substance sedative effects
  • APO-Glimepiride 1 Mg Tablets: Educator Will Show You How and When to Do This

    APO-Glimepiride 1 Mg Tablets: Educator Will Show You How and When to Do This

    APO-Glimepiride Contains the active ingredient glimepiride Consumer Medicine Information For a copy of a large print leaflet, Ph: 1800 Ask your doctor if you have any questions Talk to your doctor or pharmacist if you are 195 055 about why this medicine has been prescribed not sure whether you should start taking this for you. medicine. What is in this leaflet This medicine is available only with a doctor's Before you start to take it prescription. Tell your doctor if: This leaflet answers some common questions There is no evidence that this medicine is about APO-Glimepiride. It does not contain all of addictive. 1. You have allergies to: the available information. - any other medicines - lactose It does not take the place of talking to your doctor Before you take this medicine or pharmacist. - any other substances such as food, preservatives, or dyes All medicines have risks and benefits. Your When you must not take it 2. You have or have had any medical doctor has weighed the risks of you taking this Do not take this medicine if you have had an conditions, especially the following: medicine against the benefits this medicine is allergic reaction to: expected to have for you. - liver problems • glimepiride or other sulfonylureas - kidney problems Ask your doctor or pharmacist if you have any • antibiotics called sulphonamides - a deficiency in the enzyme in your body concerns about taking this medicine. • thiazide diuretics (a type of fluid or water called glucose-6-phosphate dehydrogenase Keep this leaflet with the medicine. tablets) (G6PD) You may need to read it again.
  • Marrakesh Agreement Establishing the World Trade Organization

    Marrakesh Agreement Establishing the World Trade Organization

    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX